{
    "clinical_study": {
        "@rank": "62252", 
        "arm_group": [
            {
                "arm_group_label": "LEO 90100", 
                "arm_group_type": "Experimental", 
                "description": "LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks"
            }, 
            {
                "arm_group_label": "Aerosol foam vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks"
            }, 
            {
                "arm_group_label": "Calcipotriol BDP gel", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks"
            }, 
            {
                "arm_group_label": "Gel vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose is to compare the efficacy of treatment with LEO 90100 at Week 4 to that of\n      calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis\n      vulgaris"
        }, 
        "brief_title": "LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris", 
        "condition": "Psoriasis Vulgaris (Plaque Psoriasis)", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years or above\n\n          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and\n             skin folds) involving 2-30% of the Body Surface Area (BSA)\n\n          -  A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk\n             and limbs\n\n          -  A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and\n             limbs.\n\n        Exclusion Criteria:\n\n          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis\n\n          -  Systemic treatment with biological therapies, whether marketed or not, with a\n             possible effect on psoriasis vulgaris within the following time periods prior to\n             randomisation:\n\n               -  etanercept - within 4 weeks prior to randomisation\n\n               -  adalimumab, infliximab - within 8 weeks prior to randomisation\n\n               -  ustekinumab - within 16 weeks prior to randomisation\n\n               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever\n                  is longer)\n\n          -  Systemic treatment with all other therapies with a possible effect on psoriasis\n             vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other\n             immunosuppressants within 4 weeks prior to randomisation)\n\n          -  Subjects who have received treatment with any non-marketed drug substance (i.e. a\n             drug which has not yet been made available for clinical use following registration)\n             within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.\n\n          -  Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to\n             randomisation\n\n          -  Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation\n\n          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients)\n             within 2 weeks prior to randomisation\n\n          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D\n             analogues or prescription shampoos within 2 weeks prior to randomisation\n\n          -  Females who are pregnant, wishing to become pregnant during the trial or are\n             breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "460", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132936", 
            "org_study_id": "LP0053-1003"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "LEO 90100 aerosol foam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aerosol foam vehicle", 
                "intervention_name": "Aerosol foam vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Calcipotriol BDP gel", 
                "intervention_name": "Calcipotriol BDP gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gel vehicle", 
                "intervention_name": "Gel vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Betamethasone sodium phosphate", 
                "Calcipotriene", 
                "Calcitriol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 6, 2014", 
        "number_of_arms": "4", 
        "official_title": "LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Treatment success according to the PGA", 
            "safety_issue": "No", 
            "time_frame": "4 Weeks for LEO 90100 and 8 weeks for calcipotriol BDP gel"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132936"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}